3SBio, Hengrui withdraw biosimilar applications

3SBio Inc. (HKSE:1530) and Jiangsu Hengrui Medicine Co. Ltd. (Shanghai:600276) each withdrew NDAs for biosimilars from China FDA review, citing review policies instituted last year that require sponsors

Read the full 280 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE